Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported results from a proof-of-concept study for a novel exosome-based platform that could ...
Study indicates that noninvasive exosome-based liquid biopsy would be feasible for monitoring health and disease in people traveling in space MINNEAPOLIS, Oct. 18, 2022 /PRNewswire/ -- Bio-Techne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results